Asenapine

Molecular mass: 285.77 g/mol  PubChem compound: 163091

Active ingredient description

The mechanism of action of asenapine is not fully understood. However, based on its receptor pharmacology, it is proposed that the efficacy of asenapine is mediated through a combination of antagonist activity at D2 and 5-HT2A receptors. Actions at other receptors e.g. 5-HT1A, 5-HT1B, 5-HT2C, 5-HT6, 5-HT7, D3, and a2-adrenergic receptors, may also contribute to the clinical effects of asenapine.

Medicine classification

This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:

ATC code Group title Classification
N05AH05 Asenapine N Nervous system → N05 Psycholeptics → N05A Antipsychotics → N05AH Diazepines, oxazepines and thiazepines
Discover more medicines within N05AH05

Product monographs

Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):

Title Information Source Document Type  
SAPHRIS Tablet FDA, National Drug Code (US) MPI, US: SPL/PLR
SYCREST Sublingual tablet European Medicines Agency (EU) MPI, EU: SmPC

Structural formula

Graphic representation of the active ingredient's molecular structure

External identifiers

CAS Substance: 65576-45-6
DrugBank Drug: DB06216
KEGG Drug: D02995
PubChem Compound: 163091
RxNorm Ingredient: 784649
SNOMED-CT Concept: 443375003
Asenapine (substance)
UNII Identifier: JKZ19V908O
ASENAPINE

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.